Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity

Toxicology Letters

Volumn 192, Issue 2, 2010, Pages 141-149

  Saha, Sudipta ^a   New, Lee Sun ^a   Ho, Han Kiat ^a   Chui, Wai Keung ^a   Chan, Eric Chun Yong ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Glutathione; Hepatotoxicity; Human hepatocytes; Reactive metabolites; Thiazolidinedione; Troglitazone

Indexed keywords

CARBENE; GLITAZONE DERIVATIVE; GLUTATHIONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SUCCINIMIDE; SULFUR; TROGLITAZONE; TROSUCCINIMIDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL ASSAY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER MICROSOME; LIVER TOXICITY; METABOLITE; PRIORITY JOURNAL; PROTEIN BINDING; TANDEM MASS SPECTROMETRY;

CELL LINE; CELL SURVIVAL; CHROMANS; DRUG STABILITY; GLUTATHIONE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; LIVER FAILURE; PPAR GAMMA; PROTEIN CARBONYLATION; THIAZOLIDINEDIONES;

EID: 73749083993     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2009.10.014     Document Type: Article

References (30)

1. Alvarez-Sánchez R., Montavon F., Hartung T., and Phler A. Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. Chem. Res. Toxicol. 19 (2006) 1106-1116
2. Andrea M.A.P., Katherine E.C., Duane T.S., Ainsley W., John D.F., Peter G.S., Jean-Michel V., Michel J., Michel M.L., Benjamin F.T., John F.L., and Curtis C.H. Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens (serum-free medium/aflatoxin Bi/benzo[a]pyrene/N-nitrosodinethylamine). Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 5123-5127
3. Andrade R.J., Lucena M.I., Martin-vivaldi R., Fernandez M.C., Nogueras F., Pelaez G., Gomez-Qutes A., Garcia-Escano M.D., Bellot V., Hervas A., Cardenas F., Romero M., and Sameron J. Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. J. Hepatol. 31 (1999) 641-646
4. Baillie T.A., and Davis M.R. Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 22 (1993) 319-325
5. Camp H.S., Li O., Wise S.C., Hong Y.H., Frankowski C.L., Shen X., Vanbogelen R., and Leff T. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 49 (2000) 539-547
6. Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology 41 (2005) 237-246
7. Castillo J.R., Torello J., and Hernandez A. Liver injury caused by ebrotidine: a new example of the utility of the postmarketing surveillance. Eur. J. Clin. Pharmacol. 56 (2000) 187-189
8. He K., Woolf T.F., Kindt E.K., Fielder A.E., and Talaat R.E. Troglitazone quinine formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction. Biochem. Pharmacol. 62 (2001) 191-198
9. He K., Talaat R.E., Pool W.F., Reily M.D., Reed J.E., Bridges A.J., and Woolf T.F. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanism involved. Drug Metab. Dispos. 32 (2004) 639-646
10. Henry R.R. Thiazolidinones. Endocrinol. Metab. Clin. North Am. 26 (1997) 553-573
11. Kassahun K., Pearson P.G., Tang W., McIntosh I., Leung K., Elmore C., Dean D., Wang R., Doss G., and Baillie T.A. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 14 (2001) 62-70
12. Kassahun K., Davis M., Hu P., Martin B., and Baillie T. Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes. Chem. Biol. Interact. 90 (1994) 253-275
13. Kawai K., Kawasaki-Tokui Y., Odaka T., Tsuruta F., Kazui M., and Iwabuchi H. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneim. Forsch. Drug Res. 104 (1997) 1507-1514
14. γ. J. Med. Chem. 48 (2005) 3015-3025
15. Kostrubsky V.E., Sinclair J.F., Ramachandran V., Venkataramanan R., Wen Y.H., Kindt E., Galchev V., Rose K., Sinz M., and Strom S.C. The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures. Drug Metab. Dispos. 28 (2000) 1192-1197
16. Loi C.M., Randiniis E.J., Vassos A.B., Kazierad D.J., Koup J.R., and Sedman A.J. Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study. J. Clin. Pharmacol. 37 (1997) 1114-1120
17. Loi C.M., Alvey C.W., Vassos A.B., Randinitis E.J., Sedman A.J., and Koup J.R. Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites. J. Clin. Pharmacol. 39 (1999) 920-926
18. Malinowski J.M., and Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin. Ther. 22 (2000) 1151-1168
19. Marcsek Z.L., Kocsis Z., Szende B., and Tompa A. Effect of formaldehyde and reservatrol on the viability of vero, HepG2 and MCF-7 cells. Cell Biol. Int. 31 (2007) 1214-1219
20. Miller V.A., Benedetti F.M., Rigas J.R., Verret A.L., Pfister D.G., Straus D., Kris M.G., Crisp M., Heyman R., Loewen G.R., Truglia J.A., and Warrell Jr. R.P. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J. Clin. Oncol. 15 (1997) 790-795
21. 18) column chemistries for the UPLC-MS-MS analysis of glutathione, glutathione disulfide, and ophthalmic acid in mouse liver and human plasma. J. Chromatogr. Sci. 46 (2008) 209-214
22. Parker J.C. Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus. Adv. Drug Deliv. Rev. 54 (2002) 1173-1197
23. Patrick Y.M., Thomas N., Jan F., Elisabeth S., Gerald R., and Luca B. Comparative quantification of pharmacodynamic parameters of chiral compounds (RRR- vs. all-rac-a tocopherol) by global gene expression profiling. J. Plant Physiol. 162 (2005) 811-817
24. Ramachandran V., Kostrubsky V.E., Komoroski B.J., Zhang S., Dorko K., Esplen J.E., Strom S.C., and Venkataramanan R. Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab. Dispos. 27 (1999) 1194-1199
25. Reznick A.Z., and Packer L. Oxidative damage to proteins: spectrophotometirc method for carbonyl assay. Methods Enzymol. 233 (1994) 357-363
26. Rizvi N.A., Marshall J.L., Dahut W., Ness E., Truglia J.A., Loewen G., Gill G.M., Ulm E.H., Geiser R., Jaunakais D., and Hawkins M.J. A phase I study of LGD1069 in adults with advanced cancer. Clin. Cancer Res. 5 (1999) 1658-1664
27. Sahi J., Hamilton G., Sinz M., Barros S., Huang M., and Lesko M.J. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica 30 (2000) 273-284
28. Sherman S.I., Gopal J., Haugen B.R., Chiu A.C., Whaley K., Nowlakha P., and Duvic M. Central hypothyroidism associated with retinoid X receptor-selective ligands. N. Engl. J. Med. 340 (1999) 1075-1079
29. Smith M.T. Mechanisms of troglitazone hepatotoxicity. Chem. Res. Toxicol. 16 (2003) 679-684
30. Tetty J.N., Maggs J.L., Rapeport W.G., Primohamed M., and Park B.K. Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem. Res. Toxicol. 14 (2001) 965-974